Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affymax NV

Division of GlaxoSmithKline PLC

Latest From Affymax NV

The Resurrection of Affymax

A group of venture firms decided to buy Affymax from GSK at a bargain-basement valuation. They felt it had not merely the makings of a product company but could jumpstart the creation of a fully integrated biology/screening/chemistry drug discovery company. In effect, they bought, at a discount, a proto-Vertex that wouldn't have to wait nearly a decade to see a valuation explosion.
BioPharmaceutical Strategy

Ancile Pharmaceuticals Inc.

Ancile Pharmaceuticals believes the time is right to profit from botanicals. The FDA has recently shown a willingness to work with companies attempting to develop herbal drugs, while consumer demand for herbal dietary supplements is mushrooming. From botanicals, Ancile plans to develop patentable, proprietary ingredients that have multiple uses, and sell products based on those ingredients in the medical foods, dietary supplement and drug markets.
BioPharmaceutical Platform Technologies

Creating Glaxo Wellcome

Glaxo took over Wellcome to boost profits at risk from the Zantac patent expiration. But its R&D managers used the tumult and pain caused by the deal to revitalize an organization which had grown complacent and was ill-equipped to exploit the new technologies which were industrializing drug discovery. Productivity is way up--with no increase in budget. But has Glaxo Wellcome really accomplished its mission or is a continuing series of cost-squeezing mergers still inevitable?
BioPharmaceutical Strategy

Sunesis Pharmaceuticals Inc.

The drawbacks associated with protein drugs--including the injectable mode of delivery and the high costs of goods--have led a number of biotech and pharmaceutical companies to use their protein engineering capabilities for small molecule drug discovery. Fledging Sunesis Pharmaceuticals Inc. has leapt into the fray with what its management believes is a unique combination of robust proprietary technology and integrated capabilities in medicinal chemistry and protein engineering.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Gordon Ringold, PhD, Pres.
  • Contact Info
  • Affymax NV
    Phone: (415) 496-2300
    4001 Miranda Ave.
    Palo Alto, CA 94304
    USA
UsernamePublicRestriction

Register